858 Therapeutics
Dr. Michael G. Kharas is an Associate Investigator that leads a laboratory in the Molecular Pharmacology Program at the Memorial Sloan-Kettering Cancer Center (New York, NY, USA). Dr. Kharas is a member of the Centers for Hematological Malignancies, Stem Cell Biology, Cellular Engineering and Experimental Therapeutics. Dr. Kharas finished his postdoctoral training at Brigham and Women’s Hospital and studied how signaling pathways alters stem cell regulation with Drs. Gary Gilliland and George Daley. In 2011, he started his laboratory at MSK and focused on the controllers of cellular fate in the blood. His laboratory has uncovered new RNA regulators and how they modulate self-renewal, cell-fate decisions, and differentiation in both normal blood development and in myeloid leukemia. His laboratory is also developing small molecule inhibitors that can block the function of these RNA regulators as a potential therapeutic strategy in leukemia.
This person is not in the org chart
This person is not in any offices
858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.